Descriptor:
A mitochondria-derived 21–24 amino acid micropeptide, originally isolated from an unaffected brain region in an Alzheimer's patient. Encoded from the mitochondrial 16S rRNA (MT-RNR2 gene), Humanin is associated with cytoprotection against oxidative stress, apoptotic signaling, and mitochondrial dysfunction. Thought to play adaptive, but not curative, roles in disease and cellular stress responses.
Mechanism:
• Proposed to increase cellular resilience to oxidative stress and apoptosis
• Interacts with IGFBP proteins and apoptotic regulatory pathways
• May modulate mitochondrial signaling cascades; AMPK involvement suggested but unconfirmed
• Upregulation appears linked to cellular adaptation during oxidative damage
• Protective effects observed in neurodegeneration and ischemia models, though mechanisms remain incompletely defined
Clinical Evidence:
• Endogenous Humanin levels generally decrease with age, though findings are mixed across studies
• Elevated levels observed in type 1 diabetes and possibly late-stage type 2 diabetes
• "Rattin," the rodent equivalent, shows neuroprotection in ischemic brain and heart injury models
• Modified Humanin analogs demonstrate cytoprotective promise in preclinical models
• No robust human supplementation trials currently available
Concerns:
• No clinical validation for exogenous Humanin use
• Adaptive Humanin increases may simply reflect cellular distress, not guaranteed protection
• Complexity of Humanin’s signaling pathways limits therapeutic interpretation
• Contradictory findings regarding aging and disease-state expression
• Commercial promotion often exceeds the strength of available evidence
Verdict:
A mitochondrial micropeptide with intriguing cytoprotective effects in preclinical research. While Humanin's roles in aging, metabolism, and neurodegeneration are under investigation, human relevance remains speculative. Caution warranted until further trials emerge.
Watch Video
